Skip to content
PIL Logo

MOVICOL 13.8g sachet, powder for oral solution

Last Updated on eMC 17-Feb-2017 View document  | Norgine Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17-Feb-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Change to section 4 - how to report a side effect
  • Change to section 6 - marketing authorisation holder

Updated on 10-Dec-2015 and displayed until 17-Feb-2017

Reasons for adding or updating:

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 17-Sep-2015 and displayed until 10-Dec-2015

Reasons for adding or updating:

  • Change to section 6 - date of revision
  • Correction of spelling/typing errors

Updated on 09-Apr-2015 and displayed until 17-Sep-2015

Reasons for adding or updating:

  • Change to section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - dose and frequency
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 08-Apr-2015 and displayed until 09-Apr-2015

Reasons for adding or updating:

  • Change to section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 2 - driving and using machines
  • Change to section 3 - dose and frequency
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 5 - how to store
  • Change to section 6 - what the product contains
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 12-Jun-2013 and displayed until 08-Apr-2015

Reasons for adding or updating:

  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 6 - date of revision

Updated on 30-Nov-2010 and displayed until 12-Jun-2013

Reasons for adding or updating:

  • Change to side-effects

Updated on 22-Apr-2010 and displayed until 30-Nov-2010

Reasons for adding or updating:

  • Extra statutory information

Updated on 11-Mar-2010 and displayed until 22-Apr-2010

Reasons for adding or updating:

  • Change to side-effects
  • Change to drug interactions

Updated on 30-May-2008 and displayed until 11-Mar-2010

Reasons for adding or updating:

  • Change due to user-testing of patient information

Updated on 17-Aug-2007 and displayed until 30-May-2008

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 15-Jun-2007 and displayed until 17-Aug-2007

Reasons for adding or updating:

  • Change due to user-testing of patient information

Updated on 17-Jan-2005 and displayed until 15-Jun-2007

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 13-Jan-2005 and displayed until 17-Jan-2005

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 17-Sep-2004 and displayed until 13-Jan-2005

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 17-Sep-2004 and displayed until 17-Sep-2004

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Company contact details

Norgine Limited

Company image
Address

Norgine House, Widewater Place, Moorhall Road, Harefield, Middlesex, UB9 6NS

Fax

+44 (0)1895 825 865

Medical Information e-mail
Telephone

+44 (0)1895 826 600

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

macrogol 3350, potassium chloride, sodium bicarbonate, sodium chloride

Legal categories

P - Pharmacy

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue